Oleg Iartchouk

Vice President, Biomarkers And Genomics at SalioGen Therapeutics

Oleg Iartchouk has over 30 years of experience in the field of genomics. Oleg began their career in 1991 as a Postdoctoral Research Scientist at the Department of Molecular Genetics at École Normale Supérieure. In 1993, they became a Research Scientist at Harvard University's Department of Molecular and Cellular Biology. In 1996, they took on the role of Advanced Genomics Technologies Group Lead at Cereon Genomics LLC. In 2002, they were appointed Technology Director at ParAllele Bioscience. From 2004 to 2006, they served as an Associated Scientist and Technology Manager at the Broad Institute. From 2006 to 2010, they were the Director of Research Genomics at the Harvard Partners Center for Personalized Genomics Medicine. From 2010 to 2013, they were the Global Head of Genomics: Analytical Sciences, CBT at Novartis/NIBR. From 2021 to 2022, they were the Senior Director: Biomarkers Discovery at Natera, and is currently the Vice President, Biomarkers and Genomics at SalioGen Therapeutics.

Oleg Iartchouk received their Ph.D. in Molecular Biology from Lomonosov Moscow State University (MSU) in 1990.

Location

Boston, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


SalioGen Therapeutics

1 followers

SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.


Employees

51-200

Links